IBDEI0YM ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,15633,1,4,0)
;;=4^E11.319
;;^UTILITY(U,$J,358.3,15633,2)
;;=^5002633
;;^UTILITY(U,$J,358.3,15634,0)
;;=G40.909^^61^760^76
;;^UTILITY(U,$J,358.3,15634,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15634,1,3,0)
;;=3^Seizure Disorder NOS
;;^UTILITY(U,$J,358.3,15634,1,4,0)
;;=4^G40.909
;;^UTILITY(U,$J,358.3,15634,2)
;;=^5003865
;;^UTILITY(U,$J,358.3,15635,0)
;;=N52.9^^61^760^30
;;^UTILITY(U,$J,358.3,15635,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15635,1,3,0)
;;=3^Erectile Dysfuntion,Unspec
;;^UTILITY(U,$J,358.3,15635,1,4,0)
;;=4^N52.9
;;^UTILITY(U,$J,358.3,15635,2)
;;=^5015763
;;^UTILITY(U,$J,358.3,15636,0)
;;=I50.22^^61^760^39
;;^UTILITY(U,$J,358.3,15636,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15636,1,3,0)
;;=3^Heart Failure,Systolic,Chronic
;;^UTILITY(U,$J,358.3,15636,1,4,0)
;;=4^I50.22
;;^UTILITY(U,$J,358.3,15636,2)
;;=^5007241
;;^UTILITY(U,$J,358.3,15637,0)
;;=I50.32^^61^760^37
;;^UTILITY(U,$J,358.3,15637,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15637,1,3,0)
;;=3^Heart Failure,Diastolic,Chronic
;;^UTILITY(U,$J,358.3,15637,1,4,0)
;;=4^I50.32
;;^UTILITY(U,$J,358.3,15637,2)
;;=^5007245
;;^UTILITY(U,$J,358.3,15638,0)
;;=I50.42^^61^760^38
;;^UTILITY(U,$J,358.3,15638,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15638,1,3,0)
;;=3^Heart Failure,Systolic & Diastolic,Chronic
;;^UTILITY(U,$J,358.3,15638,1,4,0)
;;=4^I50.42
;;^UTILITY(U,$J,358.3,15638,2)
;;=^5007249
;;^UTILITY(U,$J,358.3,15639,0)
;;=I13.0^^61^760^32
;;^UTILITY(U,$J,358.3,15639,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15639,1,3,0)
;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 1-4 Chr Kdny
;;^UTILITY(U,$J,358.3,15639,1,4,0)
;;=4^I13.0
;;^UTILITY(U,$J,358.3,15639,2)
;;=^5007067
;;^UTILITY(U,$J,358.3,15640,0)
;;=I13.2^^61^760^33
;;^UTILITY(U,$J,358.3,15640,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15640,1,3,0)
;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 5 Chr Kdny
;;^UTILITY(U,$J,358.3,15640,1,4,0)
;;=4^I13.2
;;^UTILITY(U,$J,358.3,15640,2)
;;=^5007070
;;^UTILITY(U,$J,358.3,15641,0)
;;=I13.10^^61^760^34
;;^UTILITY(U,$J,358.3,15641,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15641,1,3,0)
;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 1-4 Chr Kdny
;;^UTILITY(U,$J,358.3,15641,1,4,0)
;;=4^I13.10
;;^UTILITY(U,$J,358.3,15641,2)
;;=^5007068
;;^UTILITY(U,$J,358.3,15642,0)
;;=I13.11^^61^760^35
;;^UTILITY(U,$J,358.3,15642,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15642,1,3,0)
;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 5 Chr Kdny
;;^UTILITY(U,$J,358.3,15642,1,4,0)
;;=4^I13.11
;;^UTILITY(U,$J,358.3,15642,2)
;;=^5007069
;;^UTILITY(U,$J,358.3,15643,0)
;;=E03.9^^61^760^45
;;^UTILITY(U,$J,358.3,15643,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15643,1,3,0)
;;=3^Hypothyroidism,Unspec
;;^UTILITY(U,$J,358.3,15643,1,4,0)
;;=4^E03.9
;;^UTILITY(U,$J,358.3,15643,2)
;;=^5002476
;;^UTILITY(U,$J,358.3,15644,0)
;;=C61.^^61^760^49
;;^UTILITY(U,$J,358.3,15644,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15644,1,3,0)
;;=3^Malig Neopl Prostate
;;^UTILITY(U,$J,358.3,15644,1,4,0)
;;=4^C61.
;;^UTILITY(U,$J,358.3,15644,2)
;;=^267239
;;^UTILITY(U,$J,358.3,15645,0)
;;=F11.20^^61^760^55
;;^UTILITY(U,$J,358.3,15645,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15645,1,3,0)
;;=3^Opioid Dependence,Uncomplicated
;;^UTILITY(U,$J,358.3,15645,1,4,0)
;;=4^F11.20
;;^UTILITY(U,$J,358.3,15645,2)
;;=^5003127
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0YM 3787 printed Sep 23, 2025@19:34:18 Page 2
IBDEI0YM ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,15633,1,4,0)
+2 ;;=4^E11.319
+3 ;;^UTILITY(U,$J,358.3,15633,2)
+4 ;;=^5002633
+5 ;;^UTILITY(U,$J,358.3,15634,0)
+6 ;;=G40.909^^61^760^76
+7 ;;^UTILITY(U,$J,358.3,15634,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,15634,1,3,0)
+10 ;;=3^Seizure Disorder NOS
+11 ;;^UTILITY(U,$J,358.3,15634,1,4,0)
+12 ;;=4^G40.909
+13 ;;^UTILITY(U,$J,358.3,15634,2)
+14 ;;=^5003865
+15 ;;^UTILITY(U,$J,358.3,15635,0)
+16 ;;=N52.9^^61^760^30
+17 ;;^UTILITY(U,$J,358.3,15635,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,15635,1,3,0)
+20 ;;=3^Erectile Dysfuntion,Unspec
+21 ;;^UTILITY(U,$J,358.3,15635,1,4,0)
+22 ;;=4^N52.9
+23 ;;^UTILITY(U,$J,358.3,15635,2)
+24 ;;=^5015763
+25 ;;^UTILITY(U,$J,358.3,15636,0)
+26 ;;=I50.22^^61^760^39
+27 ;;^UTILITY(U,$J,358.3,15636,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,15636,1,3,0)
+30 ;;=3^Heart Failure,Systolic,Chronic
+31 ;;^UTILITY(U,$J,358.3,15636,1,4,0)
+32 ;;=4^I50.22
+33 ;;^UTILITY(U,$J,358.3,15636,2)
+34 ;;=^5007241
+35 ;;^UTILITY(U,$J,358.3,15637,0)
+36 ;;=I50.32^^61^760^37
+37 ;;^UTILITY(U,$J,358.3,15637,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,15637,1,3,0)
+40 ;;=3^Heart Failure,Diastolic,Chronic
+41 ;;^UTILITY(U,$J,358.3,15637,1,4,0)
+42 ;;=4^I50.32
+43 ;;^UTILITY(U,$J,358.3,15637,2)
+44 ;;=^5007245
+45 ;;^UTILITY(U,$J,358.3,15638,0)
+46 ;;=I50.42^^61^760^38
+47 ;;^UTILITY(U,$J,358.3,15638,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,15638,1,3,0)
+50 ;;=3^Heart Failure,Systolic & Diastolic,Chronic
+51 ;;^UTILITY(U,$J,358.3,15638,1,4,0)
+52 ;;=4^I50.42
+53 ;;^UTILITY(U,$J,358.3,15638,2)
+54 ;;=^5007249
+55 ;;^UTILITY(U,$J,358.3,15639,0)
+56 ;;=I13.0^^61^760^32
+57 ;;^UTILITY(U,$J,358.3,15639,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,15639,1,3,0)
+60 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 1-4 Chr Kdny
+61 ;;^UTILITY(U,$J,358.3,15639,1,4,0)
+62 ;;=4^I13.0
+63 ;;^UTILITY(U,$J,358.3,15639,2)
+64 ;;=^5007067
+65 ;;^UTILITY(U,$J,358.3,15640,0)
+66 ;;=I13.2^^61^760^33
+67 ;;^UTILITY(U,$J,358.3,15640,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,15640,1,3,0)
+70 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 5 Chr Kdny
+71 ;;^UTILITY(U,$J,358.3,15640,1,4,0)
+72 ;;=4^I13.2
+73 ;;^UTILITY(U,$J,358.3,15640,2)
+74 ;;=^5007070
+75 ;;^UTILITY(U,$J,358.3,15641,0)
+76 ;;=I13.10^^61^760^34
+77 ;;^UTILITY(U,$J,358.3,15641,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,15641,1,3,0)
+80 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 1-4 Chr Kdny
+81 ;;^UTILITY(U,$J,358.3,15641,1,4,0)
+82 ;;=4^I13.10
+83 ;;^UTILITY(U,$J,358.3,15641,2)
+84 ;;=^5007068
+85 ;;^UTILITY(U,$J,358.3,15642,0)
+86 ;;=I13.11^^61^760^35
+87 ;;^UTILITY(U,$J,358.3,15642,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,15642,1,3,0)
+90 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 5 Chr Kdny
+91 ;;^UTILITY(U,$J,358.3,15642,1,4,0)
+92 ;;=4^I13.11
+93 ;;^UTILITY(U,$J,358.3,15642,2)
+94 ;;=^5007069
+95 ;;^UTILITY(U,$J,358.3,15643,0)
+96 ;;=E03.9^^61^760^45
+97 ;;^UTILITY(U,$J,358.3,15643,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,15643,1,3,0)
+100 ;;=3^Hypothyroidism,Unspec
+101 ;;^UTILITY(U,$J,358.3,15643,1,4,0)
+102 ;;=4^E03.9
+103 ;;^UTILITY(U,$J,358.3,15643,2)
+104 ;;=^5002476
+105 ;;^UTILITY(U,$J,358.3,15644,0)
+106 ;;=C61.^^61^760^49
+107 ;;^UTILITY(U,$J,358.3,15644,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,15644,1,3,0)
+110 ;;=3^Malig Neopl Prostate
+111 ;;^UTILITY(U,$J,358.3,15644,1,4,0)
+112 ;;=4^C61.
+113 ;;^UTILITY(U,$J,358.3,15644,2)
+114 ;;=^267239
+115 ;;^UTILITY(U,$J,358.3,15645,0)
+116 ;;=F11.20^^61^760^55
+117 ;;^UTILITY(U,$J,358.3,15645,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,15645,1,3,0)
+120 ;;=3^Opioid Dependence,Uncomplicated
+121 ;;^UTILITY(U,$J,358.3,15645,1,4,0)
+122 ;;=4^F11.20
+123 ;;^UTILITY(U,$J,358.3,15645,2)
+124 ;;=^5003127
